-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ALGNは2026年第1四半期に堅調な業績を達成し、売上高は前年同期比6.2%増の10億4,000万ドルとなり、市場予想を上回りました。調整後EPSは2.58ドルで、市場予想を0.29ドル上回りました。クリアアライナーの販売量は6.7%増の68万5,700ケースとなり、為替変動の影響で4,490万ドルのプラスとなりましたが、実質的な為替変動の影響を除いた実質成長率は2.6%でした。矯正歯科医向け出荷量が7.4%増、一般歯科医向け出荷量が5.6%増と、顧客セグメント全体で幅広い成長が見られ、好材料と見ています。同社は10億6,000万ドルの現金を保有する強固なバランスシートに支えられています。経営陣は、2026年度通期の売上高成長率を3~4%、クリアアライナーの販売量成長率を中一桁台、非GAAPベースの営業利益率を約23.7%とするガイダンスを再確認しました。調整後営業利益率は240ベーシスポイント拡大して21.5%となり、リストラ効果を反映しており、今後も収益性の改善を支えていくと見込まれます。同社は2億ドルの自社株買いを完了し、2026年5月からさらに2億ドルの自社株買いを実施すると発表しました。これは、株主にとって有利な資本配分を示していると当社は考えています。
Related Articles
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.